QUANTITATIVE DETERMINATION OF SILDENAFIL CITRATE IN COMMERCIAL TABLET DOSAGE FORM MARKETED IN MAIDUGURI METROPOLITAN COUNCIL (MMC)

Sani Ali Adu1*, Wole Ogunbameru1, Musa A. Sani2, Rafat Ojuolape Abdulraheem3 and Ramat B. Abdulraheem3

1Department of Pharmaceutical Chemistry, University of Maiduguri, Nigeria
2Department of Haematology, University of Ilorin Teaching Hospital, Ilorin, Nigeria
3Department of Food Science and Technology, University of Maiduguri, Nigeria

Article Received on: 04/07/12 Revised on: 05/08/12 Approved for publication: 10/09/12

*Sani Audu Ali, Department of Pharmaceutical Chemistry, Faculty of Pharmacy University of Maiduguri, PMB 1069 Maiduguri, Nigeria
Email: aliaudusani@gmail.com

ABSTRACT

A quantitative analysis was carried out to determine the claimed content of sildenafil citrate present in commercial tablet dosage forms of different brands, using the reference standard from the developed method for assay of sildenafil citrate. Nine different samples were analysed using HPLC and UV-Spectrophotometric method.

For the HPLC and UV Spectrophotometer result, Pramo V has a percentage content of 103.7% and 102.6%, power 97.5 and 96.5% Man respectively. They thus failed the analysis test as the percentage content did not fall within the standard range of 95%-105% Based on the result obtained, about 78% of drugs that contain sildenafil citrate passed the analysis, while 22% failed.

Keywords: Sildenafil, HPLC, Ultra Violet Spectrophotometry

INTRODUCTION

Sildenafil citrate is a drug popularly marketed as Viagra by Pfizer. It is a potent and selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type V (PDE V), the predominant isozyme metabolizing cGMP in the corpus cavernosum1 (Goldstein, 1998). Sildenafil citrate is chemically designated as 1-[[3-(6,7-dihydro- 1-methyl-7-oxo-3-propyl-1H-pyrazolo[ 4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate (Martindale). It is marketed as an oral agent to treat male erectile dysfunction. It is an ampholyte with pKa value 4 (pirydinium ion) and 8.8 (benzimidazole). Sildenafil citrate is twice more soluble in methanol than in water. Its solubility decreases with pH up to 9 when it starts to increase again

QUANTIFICATION OF SAMPLE USING UV SPECTROPHOTOMETRY

For perfect quantification of sample, it depends on the absorbance produced by the specific concentration of the sample and that of the standard. Thus;  

\[
\text{Percentage of Sample} = \frac{\text{Absorbance of sample}}{\text{Absorbance of Standard}} \times 100 \\
\]

Cooper et al. have developed a procedure for simultaneous determination of sildenafil and its metabolite in plasma using automated sequential trace enrichment of dialysates2 a reversed phase HPLC methods have been utilized for the determination of sildenafil citrate in dosage forms3. Cooper et al. have developed a procedure for simultaneous determination of sildenafil and its metabolite in plasma using automated sequential trace enrichment of dialysates2, a reversed phase HPLC methods have been utilized for the determination of sildenafil citrate in dosage forms2. Ashok k. also estimated the sildenafil citrate in bulk and in tablet dosage form2. All these quantitative analysis of sildenafil citrate where approved to be referenced in international journals as article to the public.

CHEMICAL STRUCTURE OF SILDENAFIL CITRATE2

http://www.chemicalbook.com/ChemicalProductProperty_EN_CB9407725.htm

GENERIC NAME, BRAND NAME AND OTHER TRADE NAMES

Generic name: sildenafil
Brand name: Viagra
Other trade names: caverta, Vega, ceagra, homograe, pramoV, teagra, and so on.

DRUG DESCRIPTION

Sildenafil Citrate is an off white crystalline powder. It is formulated as blue, film coated diamond shaped tablets. Tablets are manufactured at a dosage of 25mg, 50mg and 100mg.

Solubility: 3.5 mg/ml in water
Molecular weight: 666.7 g/mol

EXPERIMENTAL SECTION

METHOD FOR HPLC ANALYSIS

A High Performance Liquid Chromatograph system, with LC solutions data handling system
Aliquots of stock solution were further diluted with Methanol and it was sited below. Standard stock solution was prepared by dissolving 70.25 mg of SILDENAFIL STOCK SOLUTION: filtered through a 0.45m membrane filter paper. The mobile phase was sonicated for 15 min and then it was filtered through a 0.45m membrane filter paper.

**PREPARATION OF MOBILE PHASE:** Mobile phase was prepared by mixing 700 ml of acetonitrile and phosphate buffer in the ratio of 70:30 (v/v pH 7.0) at ambient temperature. Flow rate was kept at 1 ml/min, and the elution was monitored at 228 nm.

**PREPARATION OF STOCK AND STANDARD SOLUTIONS:**

The standard used was referenced from the developed method and it was sited below: Accurately weighed 25 mg of test sample into a clean dry 50 ml volumetric flask, dissolve and diluted the mark with mobile phase. Mark this solution as sample solution. This solution contains 0.5mg/ml of Sildenafil Citrate was transferred to 100 mL volumetric flask and dissolved in methanol. Then the solution was sonicated for 15 min and filtered and it was for further diluted to get the required concentration of 20ug/ml which is equivalent to 20ppm. The absorbance of the prepared sample solution was measure against methanol blank at 291±2 nm.

**METHOD USED FOR UV SPECTROPHOTOMETRIC ANALYSIS:**

A lambda 35, UV-Visible double beam spectrophotometer with 1 cm matched quartz cell was used and nine different brands of tablets of sildenafil were obtained from local stores for the analysis.

**SILDENAFIL STOCK SOLUTION:**

Standard stock solution was prepared by dissolving 70.25 mg of Sildenafil in 100 mL of methanol to get concentration of 500 μg/mL solution.

**PROCEDURE FOR CALIBRATION CURVE:**

Aliquots of stock solution were further diluted with Methanol to get working solution of 5, 10, 15, 20, 25 and 30 μg ml -1. Finally, the prepared standards were measured after standing for 5.0 min at λ max as recorded in each case against a solvent blank similarly prepared. A calibration graph of the absorbance versus the concentration of the drug was plotted. For the reason of using this reference standard, the same spectrophometric condition was adopted.

**PROCEDURE FOR THE ANALYSIS OF SAMPLE DOSAGE FORMS:**

For analysis of commercial formulations, ten tablets were taken and powdered. Tablet powder equivalent to 140.5 mg of sildenafil citrate was transferred to 100 mL volumetric flask and dissolved in methanol. Then the solution was sonicated for 15 min and filtered and it was for further diluted to get the required concentration of 20mg/ml which is equivalent to 20ppm. The absorbance of the prepared sample solution was measured against methanol blank at 291±2 nm.

**RESULTS AND DISCUSSION**

Calculation of content of tablet on HPLC:

Content of tablet (%) = Peak Area of sample × 100 / Peak Area of standard

Calculation of content of tablet on UV Spectrophotometer:

Content of tablet (%) = Absorbance of sample × 100 / Absorbance of standard

**HPLC graphical result is shown bellow;**

**Table 1 showing information contained on the samples**

<table>
<thead>
<tr>
<th>Name of sample</th>
<th>Batch Number</th>
<th>Manufacturing date</th>
<th>Expiry date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramo V</td>
<td>R D001M</td>
<td>April,2010</td>
<td>March,2013</td>
</tr>
<tr>
<td>Power</td>
<td>VP02</td>
<td>April,2009</td>
<td>September,2011</td>
</tr>
<tr>
<td>Vega</td>
<td>S103</td>
<td>June,2009</td>
<td>May,2012</td>
</tr>
<tr>
<td>Man-Up</td>
<td>T91016</td>
<td>October,2009</td>
<td>September,2012</td>
</tr>
<tr>
<td>Soga</td>
<td>GS 12</td>
<td>July, 2009</td>
<td>December,2011</td>
</tr>
<tr>
<td>Ceagra</td>
<td>F119209</td>
<td>November,2009</td>
<td>October,2012</td>
</tr>
<tr>
<td>Caverta</td>
<td>2150151</td>
<td>April,2010</td>
<td>March,2012</td>
</tr>
<tr>
<td>Homogra</td>
<td>L1736</td>
<td>August,2009</td>
<td>July,2012</td>
</tr>
<tr>
<td>Teagra</td>
<td>UTT09</td>
<td>August,2008</td>
<td>July,2011</td>
</tr>
</tbody>
</table>

**Table 2 showing percentage content of tablets in the samples using HPLC and UV-Spectrophotometry:**

<table>
<thead>
<tr>
<th>SAMPLES</th>
<th>HPLC %</th>
<th>UV-Spectrophotometry %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pramo V</td>
<td>103.7</td>
<td>102.6</td>
</tr>
<tr>
<td>Power</td>
<td>97.5</td>
<td>96.3</td>
</tr>
<tr>
<td>Vega</td>
<td>91.3</td>
<td>91.4</td>
</tr>
<tr>
<td>Man-Up</td>
<td>95.2</td>
<td>96.9</td>
</tr>
<tr>
<td>Soga</td>
<td>104.2</td>
<td>104.6</td>
</tr>
<tr>
<td>Ceagra</td>
<td>109.1</td>
<td>114.4</td>
</tr>
<tr>
<td>Caverta</td>
<td>101.9</td>
<td>100.2</td>
</tr>
<tr>
<td>Homogra</td>
<td>102.8</td>
<td>100.5</td>
</tr>
<tr>
<td>Teagra</td>
<td>99.0</td>
<td>98.4</td>
</tr>
</tbody>
</table>

**DISCUSSION**

In tablet production, uniformity of tablet quantity is very important so as to ascertain the specified quantity of active ingredient contained in the dosage form. Therefore, in quantitative analysis, percentage tablet content is determined to quantify the active ingredient being claimed by the label. From the result obtained, it was found that seven out of the analysed sample passed the test. For the HPLC and UV Spectrophotometer result, Pramo V has a percentage content of 103.7% and 102.6%, power 97.5 and 96.5% Man-up 95.2% and 96.9%, soga 104.2% and 104.6, caverta 101.9% and 100.2%, Homogra 102.8% and 100.5%, Teagra 99.0% and 98.4%, vega 91.3% and 91.4% and ceagra 109.1% and 114.4%, respectively. It was observed that both vega and ceagra samples has a percentage concentration of 91.3, 91.4% and 109.1%, 114.4% respectively. They thus failed the analysis test as the percentage content did not fall within the standard range of 95%-105%.
CONCLUSION
Based on the result obtained, about 78% of drugs that contain sildenafil citrate passed the analysis, while 22% failed. Thus Vega sample was observed to contain 91.3% and 91.4% of 100mg of sildenafil citrate of label claims, and ceagra sample contain 109.1% and 114.4% of 100mg of sildenafil citrate of the label claim from the result of both HPLC and UV-Spectrophotometric method respectively. This studies thus emphasized on the quantitative determination of sildenafil citrate in commercial tablet dosage forms.

REFERENCES

Source of support: Nil, Conflict of interest: None Declared